Pharmaxis (PXS: $0.061) CEO Gary Phillips said the company is approaching a point when it is about to realise the benefits from the investment that has been made in its clinical programs, with the results from two clinical trials forthcoming. Phillips said it has taken several years to get to this point.

Immuron's (IMC: $0.078) business was severely impacted by the pandemic, with its lead product, Travelan, sold to prevent traveller's diarrhea. Sales fell from $2.7 million in FY2020 to just $166,000 in FY2021.

Imugene (IMU: $0.15) has in-licensed three core technologies. The first and the one on which the company was founded was HER-Vaxx (2013). This technology stimulates the body to develop antibodies against HER2, which is present on breast and gastric tumours in specific patients (who are HER2 positive).

Imricor (IMR: $0.29) is seeking to introduce a new standard-of-care in cardiac ablation procedures. That involves using MRI rather than x-ray to guide the procedures which arguably provides better real-time, functional information on how best to correct irregular heart function.

Chimeric Therapeutics (CHM: $0.076) is commercialising cell therapy technologies sourced from three US research institutions to treat a range of poorly addressed cancers. Patients with these diseases had a five-year survival expectation of just 5% - 27%.

Anteris Technologies (AVR: $21.50) is commercialising the DurAVR aortic heart valve which is implanted by catheter rather than open chest surgery. It is seeking to launch its product in coming years in a market estimated to be worth US$10 billion in 2028, based on only a 15%-20% penetration base of the current patients, according to CEO Wayne Paterson.

Aroa Biosurgery (ARX: $1.08) describes itself as a high growth tissue regeneration company. That high growth has been achieved in FY2023 (its financial year ends 31 March) with annual sales expected to reach the target NZ$60 - NZ$62 million, up at least 54% on the previous year.

Terms: Trofinetide brand name is DAYBUE in North America.

A book was written in 1994 about US biotech company Vertex Pharmaceuticals called The Billion Dollar Molecule. Last week Neuren Pharmaceuticals (NEU: $13.23) may have been successful in achieving that quest - with approval in the US, through its partner Acadia Pharmaceuticals, of the drug which has been renamed DAYBUE (formerly trofinetide) for the treatment of Retts syndrome.